Cargando…

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review

Inconsistent therapeutic responses have been observed among patients with sickle cell anemia (SCA) undergoing hydroxyurea (HU) following the adoption of the standardized protocol. Moreover, this treatment regimen necessitates a prolonged period to reach the maximum tolerated dose in which beneficial...

Descripción completa

Detalles Bibliográficos
Autores principales:	dos Santos Neres, Joelma Santana, Yahouédéhou, Sètondji Cocou Modeste Alexandre, Goncalves, Marilda Souza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301107/ https://www.ncbi.nlm.nih.gov/pubmed/37375804 http://dx.doi.org/10.3390/ph16060857

Ejemplares similares

Sickle Cell Anemia: Variants in the CYP2D6, CAT, and SLC14A1 Genes Are Associated With Improved Hydroxyurea Response
por: Yahouédéhou, Sètondji Cocou Modeste Alexandre, et al.
Publicado: (2020)

Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters
por: Yahouédéhou, Sètondji Cocou Modeste Alexandre, et al.
Publicado: (2018)

Association of laboratory markers and cerebral blood flow among sickle cell anemia children
por: Adanho, Corynne Stéphanie Ahouéfa, et al.
Publicado: (2022)

Hydroxyurea Scavenges Free Radicals and Induces the Expression of Antioxidant Genes in Human Cell Cultures Treated With Hemin
por: Santana, Sânzio Silva, et al.
Publicado: (2020)

Priapism in sickle cell disease: Associations between NOS3 and EDN1 genetic polymorphisms and laboratory biomarkers
por: Figueiredo, Camylla Vilas Boas, et al.
Publicado: (2021)

TGFBR3 Polymorphisms (rs1805110 and rs7526590) Are Associated with Laboratory Biomarkers and Clinical Manifestations in Sickle Cell Anemia
por: Santiago, Rayra Pereira, et al.
Publicado: (2020)

Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC)
por: da Guarda, Caroline Conceição, et al.
Publicado: (2020)

Effect of N(Epsilon)-(carboxymethyl)lysine on Laboratory Parameters and Its Association with β(S) Haplotype in Children with Sickle Cell Anemia
por: Ndidi, Uche Samuel, et al.
Publicado: (2019)

Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients
por: Guarda, Caroline C., et al.
Publicado: (2019)

Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia
por: Yahouédéhou, Sètondji Cocou Modeste Alexandre, et al.
Publicado: (2019)

Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review
por: Miranda, Gustavo Marinho, et al.
Publicado: (2021)

Evaluation of 2D and 3D Erythroid Differentiation Protocols Using Sickle Cell Disease and Healthy Donor Induced Pluripotent Stem Cells
por: Martins, Gabriele Louise Soares, et al.
Publicado: (2023)

Investigation of Lipid Profile and Clinical Manifestations in SCA Children
por: da Guarda, Caroline Conceição, et al.
Publicado: (2020)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Role of paraoxonase 1 activity and PON1 gene polymorphisms in sickle cell disease
por: Menezes, Joelma Figueiredo, et al.
Publicado: (2023)

A Description of the Hemolytic Component in Sickle Leg Ulcer: The Role of Circulating miR-199a-5p, miR-144, and miR-126
por: Santos, Edvan do Carmo, et al.
Publicado: (2022)

Leg Ulcers in Sickle Cell Disease: A Multifactorial Analysis Highlights the Hemolytic Profile
por: Santos, Edvan do Carmo, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia
por: Rankine-Mullings, Angela, et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Comment on “Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia”()
por: Souza Goncalves, Marilda
Publicado: (2014)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia
por: Vinhaes, Caian L., et al.
Publicado: (2020)

Influence of βS-globin haplotypes hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia
por: Laurentino, Marília Rocha, et al.
Publicado: (2014)

Comment on “Influence of βS-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia”
por: de Souza Torres, Lidiane
Publicado: (2014)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil
por: Teixeira Neto, Paulo Florentino, et al.
Publicado: (2011)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
por: Dhar, Arushi, et al.
Publicado: (2021)

Genetic Polymorphisms Associated with Environmental Exposure to Polycyclic Derivatives in African Children
por: de Oliveira, Rodrigo Mota, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pumn0tn5b1dc7kcr9f1iujc9ge